Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label valemetostat monotherapy in relapsed/refractory B-cell lymphoma
2020-005225-81Phase 2Active
- Sponsor
- LYSARC
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of valemetostat in mature B-cell lymphoma, sponsored by LYSARC. Primary endpoint: Overall response rate. Started Apr 2021; status: active.
02
Drugs
valemetostat
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on 2020-005225-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005225-81.